Boston – September 16, 2026 -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ) said Chief Financial Officer Tom Fitzgerald is retiring, effective immediately, and will be succeeded on an interim basis by John Tattory.
Fitzgerald exits after eight years steering TransCode through IPO and acquisitions
Fitzgerald has served as CFO since July 2018, a tenure spanning the company's initial public offering, the launch of clinical development for lead candidate TTX-MC138, the acquisition of Polynoma, and a license agreement with Oncolytics. He resigns as CFO and as a company director effective immediately but will remain to provide transition services.
Chairman and CEO Philippe P. Calais credited Fitzgerald with keeping the company funded from its early discovery-stage days. "Tom has worked tirelessly to keep us funded and on track," Calais said.
Tattory brings 25 years of biotech finance and capital-raising experience
Tattory takes over as Interim Chief Financial Officer effective immediately. He has more than 25 years of financial and operational leadership across pharmaceutical, medical device and biotechnology companies, spanning development stage through commercialization. He began his career at Ernst & Young LLP before serving as Finance Director at Bristol-Myers Squibb and Tyco International.
Tattory previously held CFO roles at Cerapedics, Inc. and Windtree Therapeutics, Inc. (Nasdaq: WINT). He is currently a Managing Director at global advisory firm Stout Risius Ross, LLC, where he provides Consulting CFO services to privately held life science companies, with expertise in buyside and sellside capital raising, financial planning and public financial reporting.
Leadership change comes as TransCode advances its oncology pipeline
TransCode is developing TTX-MC138 to treat metastatic tumors that overexpress microRNA-10b, alongside a broader pipeline of immuno-oncology candidates following its Polynoma acquisition and Oncolytics licensing deal.